Coherus, J&J agree to evaluate combination prostate cancer treatment
Johnson & Johnson (JNJ) has agreed to supply Coherus Oncology (CHRS) with its bispecific antibody pasritamig to...
Tag: JNJ
Insider trades: JNJ, Intel, IBM among notable names
A weekly overview of insider trading, highlighting significant purchases and sales by investors, directors, and executives....
J&J wins EU backing for Akeega label expansion
Johnson & Johnson (JNJ) announced on Friday that an expert panel of the EU drug regulator, the European Medicines...
America’s strongest brands in 2026, ranked
In the U.S., brand strength skews toward trust, reliability, and value for money. YouGov’s latest survey shows household...
4 stocks to watch on Friday: VZ, XOM, JNJ, SOFI
Stock index futures were lower on Friday as investors continued to digest a wave of corporate earnings as the selloff looked...
J&J gets dismissal of fraud claims tied to talc bankruptcy
A New Jersey federal judge has dismissed a lawsuit that claimed Johnson & Johnson (JNJ) engaged in fraud by using...
Johnson & Johnson upgraded at Morgan Stanley on growth outlook
Morgan Stanley upgraded Johnson & Johnson (JNJ) to Overweight from Equal-Weight on Wednesday, noting that the New...
J&J’s Darzalex Faspro gains another multiple myeloma indication
The U.S. FDA has approved Johnson & Johnson's (JNJ) Darzalex Faspro (daratumumab and hyaluronidase) along with...
Johnson & Johnson outlines double-digit growth ambition by end of decade as 2026 sales set to surpass $100B
Earnings Call Insights: Johnson & Johnson (JNJ) Q4 2025 Joaquin Duato, CEO & Chairman, opened by emphasizing, "We...
J&J talc litigation advances as expert testimony is approved
A court-designated special master has recommended that plaintiffs accusing Johnson & Johnson (JNJ) of marketing...